It’s official: Emerging Therapy Solutions ranked #39 on the Minneapolis/St. Paul Business Journal (MSPBJ) 2026 Fast 50 list of the Twin Cities’ fastest-growing private companies!

Growth like this doesn’t happen without an exceptional team, trusted clients and partners, and a shared commitment to solving increasingly complex challenges in healthcare.

As cell and gene therapies, transplants and other high-cost complex care continue to evolve, we’re continuing to grow and expand upon our 30+ years of expertise to help payers anticipate what’s ahead, manage emerging risks and achieve their goals in a rapidly changing healthcare landscape.

Thank you to the Minneapolis/St. Paul Business Journal for the recognition and for bringing together so many growing companies from across our community.

What does it take to manage the growing clinical and financial complexity of high-cost therapies?

ETS CEO Ashley Hume and SVP, Strategic Partnerships Chris Ford brought that conversation to the World 50 Accelerator Fall 2026 Employer Benefit Accelerator Roundtable, Oct. 1-2 in Dallas.

They shared the ETS perspective on preparing for the impact of specialty medications, transplants and cell and gene therapies, including how employers can identify risk earlier, support informed clinical decisions and manage costs more strategically.

For the first time since the event was known as the Employer Health Innovation Roundtable, more than 90 employer member companies will come together in one combined Roundtable focused on benefits innovation, cost management and strategic health care partnerships.

We’re excited to share that Emerging Therapy Solutions has been named a 2026 Fast 50 honoree by the Minneapolis/St. Paul Business Journal (MSPBJ)!

Fast 50 recognizes the Twin Cities’ fastest-growing private companies by revenue.

For ETS, this recognition reflects the continued growth of our team, the trust of our clients and partners, and the increasing need for specialized support as payers navigate cell and gene therapies, transplants and other high-cost complex care.

We’re grateful to everyone who has been part of our growth.

Press release: https://www.bizjournals.com/twincities/news/2026/08/12/business-journal-announces-2026-fast-50.html?b=1786478635^22714909

The specialty pharmacy pipeline is evolving quickly — and employers need to be ready for what’s next. ETS CEO Ashley Hume took the stage as a featured speaker as part of “The Specialty Pipeline: Can Employers Afford What’s Coming?” conversation at the Northeast Business Group on Health Pharmacy Benefits 2026 conference.

The session explored how employers can prepare for the growing impact of specialty medications, gene therapies and other emerging treatments while balancing affordability and access. We’re proud to support these important conversations about the future of healthcare.

Event Recap and Photo Gallery: Pharmacy Benefits 2026

The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.

FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A | FDA

Emerging Therapy Solutions CEO Ashley Hume joined other leaders from across the oncology community Sept. 15 at the Community Oncology Alliance Payer Exchange & Innovation Summit, an invite-only gathering focused on improving value, reducing costs and advancing quality in cancer care.

Ashley participated in a panel on Transformative Business Models for Delivering Cellular Therapy, exploring findings from COA’s Cellular Therapy Survey, barriers to access and evolving business models, including carve-out and partnership approaches that can help address financing and reimbursement challenges.

With decades of experience navigating high-cost and complex care, ETS brings an important perspective on what it takes to make access to emerging therapies more sustainable while supporting a positive patient experience.

BCS Financial published the Firm & Final episode “LIVE from RiskNavigator 2026” on September 10, 2026, featuring Ashley Hume of Emerging Therapy Solutions alongside Pat Gleason, Jim Clement, and Ramesh Jayasuriya.

Listen to “LIVE from RiskNavigator 2026” on BCS Financial 

Emerging Therapy Solutions was proud to support the conversations helping payers, employers and risk partners prepare for what’s ahead at the 2026 MCRA (Managed Care Risk Association) Annual Conference.

One of those conversations was led by Ashley Hume, CEO of ETS, during her Sept. 16 session: “Managing the Unmanageable: Cell & Gene Therapy Risk in a Rapidly Evolving Market”.

Drawing on ETS’s decades of experience helping organizations navigate high-cost, complex care, Ashley shared what ETS has learned about anticipating cell and gene therapy exposure, evaluating financial risk and preparing before a claim occurs.

Intellia Therapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). The FDA granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) date of March 10, 2027.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license?utm_content=385521070&utm_medium=social&utm_source=linkedin&hss_channel=lcp-37897480